This review summarises key aspects and clinical practice implications of POLARIX, a phase 3 randomised controlled trial that evaluated Pola-R-CHP, a modified regimen of R-CHOP (rituximab added to cyclophosphamide, doxorubicin, vincristine, and prednisone) in which vincristine was replaced with polatuzumab vedotin, compared with standard R-CHOP in patients with previously-untreated diffuse large B-cell lymphoma (DLBCL). The main findings were a statistically significant progression-free survival benefit at two years in patients who received Pola-R-CHP versus those who received R-CHOP and a similar safety profile in the two treatment groups. These findings have been confirmed in a 5-year follow-up analysis of POLARIX.
This publication has been commissioned and funded by Roche.
Please login below to download this issue (PDF)